Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price traded up 0.3% during trading on Wednesday . The stock traded as high as C$9.00 and last traded at C$8.01. Approximately 700 shares changed hands during mid-day trading, a decline of 55% from the average daily volume of 1,550 shares. The stock had previously closed at C$7.99.
Devonian Health Group Stock Up 0.3%
The company has a 50-day moving average of C$8.84 and a two-hundred day moving average of C$10.47. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The company has a market capitalization of C$22.28 million, a PE ratio of -3.56 and a beta of 0.03.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
